利记·sbobet(中国)-唯一官方网站

En

Our Company

Back

Our Company

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China

About Company
Leadership
Honor
Brand Culture
Member Companies

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
Our Business

Back

Our Business

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Pharmaceutical Manufacturing
Vaccines
Medical Devices
Medical Diagnosis
Healthcare Services
Pharmaceutical Distribution And Retail

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
R&D

Back

R&D

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

Global R&D Center
R&D Pipeline
Innovation Platform
Clinical Development
R&D News

Guided by innovation and internationalization, the company continuously enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
Sustainability

Back

Sustainability

In pursuit of sustainable development of talents and products is the social responsibility concept of Fosun Pharma.

Social Responsibility Strategy
Special Fund For Fosun Pharma Health Care Initiative
Social Welfare
CSR News
Relevant Policies
ESG And Sustainability Report Download

Fosun Pharma has incorporated sustainable development into the Group's overall development strategy, emphasizing long-term ESG governance capabilities, and established a three-level ESG governance structure supervised by the board of directors (the “Board”), implemented by the ESG Committee, and executed by the ESG Working Group. The ESG Committee of the Board is responsible for formulating and promoting the Group's ESG vision, goals, and strategies, and provides advice to the Board; the ESG Working Group is responsible for sorting out key ESG issues, formulating sustainable development quantitative targets, and tracking progress. The ESG Committee and the ESG Working Group are committed to integrating ESG concepts into corporate operations and enhancing the company's sustainability.
Investor Relations

Back

Investor Relations

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

Announcements
Corporate Governance
Financial Report
Investor Presentation Materials
FAQS
Investor Contact

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
News

Back

News

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China.

Press Release
Member Companies News
Media Resources
Media Contact

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Careers

Back

Careers

Some top talent with strong entrepreneurship gathers here with us.

Talent Concept
Incentives
Life At Fosun Pharma

We are looking for people that recognize and practice our cultural values, and can learn fast to create continuous value; possess profound professional knowledge of the industry, a wide vision of different regions, and global-level expertise in a certain field. We will also be committed to cultivating international top talent with outstanding performance and great potential.

2020-10-10

First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency Evaluation

Recently, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), a member enterprise of Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma"), received the Notice on Approval of Supplementary Drug Application for Perphenazine Tablets (2 mg, 4 mg) (No.: 2020B04654, 2020B04655) from NMPA. The drug is the first of its kind in China to pass the consistency evaluation of quality and efficacy of generic drugs.

Perphenazine Tablets is indicated for the treatment of schizophrenia and severe nausea and vomiting. By September 2020, Zhaohui Pharmaceutical has invested a cumulative R&D amount of about RMB 10.6 million (not audited) for the consistency evaluation at this stage.

Perphenazine Tablets has successfully passed the generics consistency evaluation, which will help improve the product's competitiveness, enhance the product's market position and bring new market opportunities.

Previous：Fochon Pharmaceuticals, Ltd. (Subsidiary of Fosun Pharma) Announces Licensing Agreement with Eli Lilly for Novel Selective BCL-2 Inhibitor Next：Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA